Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities
| Autor: | Maria Valicenti-McDermott, Howard B. Demb |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Drug
Male Sleep Wake Disorders medicine.medical_specialty Adolescent media_common.quotation_subject MEDLINE Aripiprazole Child Behavior Disorders Quinolones Off-label use Piperazines Body Mass Index Intellectual Disability Drug approval medicine Humans Pharmacology (medical) Clinical efficacy Autistic Disorder Psychiatry Child Drug Approval media_common Reactive Attachment Disorder Dose-Response Relationship Drug Mood Disorders Follow up studies Aggression Psychiatry and Mental health Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Child Preschool Pediatrics Perinatology and Child Health Impulsive Behavior Female Psychology Body mass index Self-Injurious Behavior Clinical psychology medicine.drug Antipsychotic Agents Follow-Up Studies |
| Zdroj: | Journal of child and adolescent psychopharmacology. 16(5) |
| ISSN: | 1044-5463 |
| Popis: | The aim of this study was to report on the clinical efficacy and side effects of aripiprazole in treating behavioral symptoms of children with a developmental disability (DDs).A retrospective chart review of the first 32 children treated with aripiprazole at an urban clinic for children with DD was conducted.Ages ranged from 5 to 19 years; 9 (28%) were female. Twenty four had diagnoses within the autistic spectrum and 18 had mental retardation (MR). Other disorders included: attention-deficit/hyperactivity disorder/disruptive behavior disorders (n = 13), mood disorders (n = 7), reactive attachment (n = 2), and sleep disorders (n = 2). Target symptoms included aggression, hyperactivity, impulsivity and, self-injurious behaviors. Twenty eight of the children were switched from another antipsychotic. The mean daily aripiprazole starting dose was 7.1 +/- 0.32 mg (0.17 mg/kg/day) and the mean daily maintenance dose was 10.55 +/- 6.9 mg (0.27 mg/kg/day). Aripiprazole had been used for a period between 6 and 15 months. Improvement in target symptoms was found in 56%. When treating a child with MR, the concomitant presence of an autistic spectrum diagnosis predicted a worse outcome. Side effects were reported in 16 (50%), with the most frequent being sleepiness (n = 6). Mean body mass index (BMI) rose from 22.5 to 24.1 (p = 0.003) over the follow up period, with changes in the BMI z scores. These changes were more pronounced in children younger than 12 years.These results with aripiprazole in this difficult-to-treat population suggest that this medication warrants controlled studies of its effectiveness and safety. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|